Syra Health Corp 8-K, filed Aug 11, 2026
Syra Health Corp (SYRA)
About this 8-K
Syra Health Corp filed this 8-K on August 11, 2026.
Items reported
- Item 2.02: Financial results
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (Commission | (I. R. S. Employer | ||
| of incorporation) | File Number) | Identification No.) |
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| OTCQB |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02. Results of Operations and Financial Conditions.
On August 11, 2026, Syra Health Corp. issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
The information in this report, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. In addition, the exhibit furnished herewith contain statements intended as “forward-looking statements” that are subject to the cautionary statements about forward-looking statements set forth in such exhibit.
Item 9.01 Financial Statements and Exhibit
(d) Exhibits.
The following exhibits are filed with this Current Report on Form 8-K:
Exhibit Number |
Description | |
| 99.1 | Press Release dated August 11, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SYRA HEALTH CORP. | ||
| Date: August 11, 2026 | By: | /s/ Priya Prasad |
Priya Prasad Chief Financial Officer | ||
Exhibit 99.1
Syra Health Achieves 23% Revenue Growth, Improves Gross Margin to 44.5% in Second Consecutive Profitable Quarter
| ● | Syra Health sustained profitability in Q2 2026, following the Company’s first profitable quarter in Q1 2026, delivering net income of $250,242 compared with a net loss of $(63,596) in the prior-year period. | |
| ● | Q2 2026 revenue grew 23% year-over-year to $2.4 million. | |
| ● | Earnings per share (EPS) improved to $0.02 in Q2 2026 from a loss of $(0.01) in Q2 2025. | |
| ● | Gross margin increased to 44.5% in Q2 2026, up from 38.7% in Q2 2025. |
Carmel, Ind., August 11, 2026 / PRNewswire – Syra Health Corp. (OTCQB: SYRA) (“Syra Health” or the “Company”), an integrated healthcare solutions company powering better health outcomes through prevention-focused, accessible, and affordable solutions, announced today its financial results for the second quarter ended June 30, 2026.
Q2 2026 Financial Highlights
Syra Health continued to be profitable in Q2 2026, with net income of $250,242 compared to a net loss of $(63,596) in the prior-year period, an improvement of approximately $314,000 or 493% year-over-year.
Total revenue of $2.4 million for the quarter ended June 30, 2026, was up 23% when compared to $1.9 million in the prior-year period.
Revenue growth outpaced cost growth in Q2 2026, resulting in gross margin expansion of approximately 584 basis points to 44.5%, up from 38.7% in the prior-year period, the highest quarterly gross margin in the Company’s history.
EPS improved to $0.02 from a loss of $(0.01) in the prior-year period, reflecting a $0.03 per share year-over-year improvement.
EBITDA increased by $307,000 year-over-year, improving from a loss of $(53,760) in Q2 2025 to positive EBITDA of $253,200 in Q2 2026.
For the six months ended June 30, 2026, net income was $491,221 compared to a net loss of $(535,861) in the prior-year period, and net cash provided by operating activities was $643,183 compared to $85,754 in the prior-year period.
2026 Financial Outlook
Following two consecutive profitable quarters, Syra Health remains focused on achieving its previously stated target of full-year profitability for 2026. Certain revenue recognition, timing, and contract milestones are expected to continue to contribute to quarterly variability.
| -1- |
Recent Operational Highlights
Syra Health received contract extensions from several existing customers, including a one-year renewal of its public health contract with Wake County Public Health in North Carolina. The Company also secured a one-year extension of its healthcare workforce contract with the Indiana Veterans’ Home. The Company has been awarded an amendment to its existing Indiana FSSA (Family & Social Services Administration) contract with DDRS (Division of Disability and Rehabilitative Services), to extend a learning management platform to the state’s Bureau of Disability Services, through October 2028.
Syra Health has established a Business Advisory Council to support strategic market expansion and identify growth opportunities.
The Company anticipates approval for the CMS ACCESS Model in partnership with HealthSync in the near term, which is expected to serve as a durable source of revenue for Syra Health over the next 10 years.
Management Commentary
Greg Alexander, CEO of Syra Health, said, “Q2 2026 represents another important milestone in Syra Health’s evolution as we continue to execute against our growth strategy to build a leading, sustainable healthcare solutions company. Following our first ever profitable quarter in Q1, we achieved continued profitability in Q2, grew revenue by 23% year-over-year, and expanded our gross margin to 44.5%, demonstrating the strength of our business model and the impact of our focus on operational efficiency, disciplined growth, and higher-value solutions.
We are encouraged by the continued momentum across our business, including growth in our population health solutions, contract extensions with existing customers, progress toward CMS ACCESS Model approval, and continued demand for our healthcare workforce solutions. These achievements reflect the confidence our customers place in Syra Health and our ability to address some of healthcare’s most pressing challenges around access, affordability, and outcomes.
As we look ahead, we remain focused on sustaining full-year profitability, while continuing to grow our customer base and deliver innovative solutions that improve health outcomes. We believe our diversified portfolio, technology-enabled solutions, and strong market partnerships position Syra Health for continued long-term growth and value creation for our shareholders.”
Q2 2026 Financial Results
Revenue for the second quarter of 2026 grew to $2.4 million, an increase of 23% when compared to $1.9 million in the second quarter of 2025. Growth was led by the Company’s high-margin population health solutions, which grew 8% year-over-year to $1,716,310 million from $1,583,752 million in Q2 2025.
Healthcare workforce revenue increased 87% year-over-year, from $362,447 to $678,113 as demand for our healthcare workforce solutions grew to address critical workforce shortages and the Company continued to focus on better margin contracts.
Gross profit margin expanded 580 basis points to 44.5% in the second quarter of 2026, compared with 38.7% in the prior year period, reflecting revenue mix and continued operating leverage.
Operating expenses reflected continued cost management, while allowing for strategic spending to support growth. Salaries and benefits increased 20% to $392,136 in Q2 2026 from $326,354 in the prior-year period, reflecting investments in talent to support business expansion. Professional services decreased 16% to $138,019 in Q2 2026 from $164,939 in Q2 2025, while selling, general and administrative expenses also declined 18% to $236,485 compared with $289,070 in the prior-year period. Research and development expenses increased 59% to $47,351 in Q2 2026 from $29,712 in Q2 2025, reflecting allocations in our technology-enabled solutions. Depreciation expense decreased 88% to $741 from $5,978 in the year-ago period.
Net cash provided by operating activities for the six months ended June 30, 2026, was $643,183, compared to $85,754 in the prior-year period. Cash and cash equivalents were $2.1 million as of June 30, 2026, compared to $2.9 million as of March 31, 2026, and $1.6 million as of December 31, 2025, reflecting a $552,000 increase in accounts receivable and the recognition of deferred revenue that had been billed in advance during the first quarter.
Cash on hand was $2.1 million and no long-term debt as of June 30, 2026.
| -2- |
SYRA HEALTH CORP.
BALANCE SHEETS
| June 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 2,123,747 | $ | 1,614,733 | ||||
| Accounts receivable, net | 1,470,023 | 918,374 | ||||||
| Other current assets | 153,384 | 205,423 | ||||||
| Total current assets | 3,747,154 | 2,738,530 | ||||||
| Property and equipment, net | 5,192 | 6,986 | ||||||
| Right-of-use asset | 77,644 | 27,401 | ||||||
| Total assets | $ | 3,829,990 | $ | 2,772,917 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 195,595 | $ | 247,520 | ||||
| Accounts payable, related party | 125,000 | 72,000 | ||||||
| Accrued expenses | 220,333 | 194,821 | ||||||
| Deferred revenue | 505,886 | 16,611 | ||||||
| Current portion of operating lease liability, related party | 77,644 | 27,401 | ||||||
| Notes payable | 71,694 | 116,386 | ||||||
| Total current liabilities | 1,196,152 | 674,739 | ||||||
| Non-current portion of operating lease liability, related party | - | - | ||||||
| Total liabilities | 1,196,152 | 674,739 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares designated, issued and outstanding | - | - | ||||||
| Class A common stock, $0.001 par value, 100,000,000 shares authorized, 13,839,169 and 11,339,169 shares issued and outstanding, respectively | 13,839 | 11,339 | ||||||
| Convertible class B common stock, $0.001 par value, 5,000,000 shares authorized, 350,000 and 600,000 shares issued and outstanding, respectively | 350 | 600 | ||||||
| Additional paid-in capital | 11,848,954 | 11,806,765 | ||||||
| Accumulated deficit | (9,229,305 | ) | (9,720,526 | ) | ||||
| Total stockholders’ equity | 2,633,838 | 2,098,178 | ||||||
| Total liabilities and stockholders’ equity | $ | 3,829,990 | $ | 2,772,917 | ||||
| -3- |
SYRA HEALTH CORP.
STATEMENTS OF OPERATIONS
(Unaudited)
| For the Three Months Ended | For the Six Months Ended | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Net revenues | $ | 2,394,423 | $ | 1,946,199 | $ | 4,667,943 | $ | 3,803,973 | ||||||||
| Cost of services | 1,328,120 | 1,193,304 | 2,630,385 | 2,461,922 | ||||||||||||
| Gross profit | 1,066,303 | 752,895 | 2,037,558 | 1,342,051 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Salaries and benefits | 392,136 | 326,354 | 764,245 | 833,561 | ||||||||||||
| Professional services | 138,019 | 164,939 | 325,160 | 388,965 | ||||||||||||
| Research and development expenses | 47,351 | 29,712 | 54,272 | 66,885 | ||||||||||||
| Selling, general and administrative expenses | 236,485 | 289,070 | 449,532 | 576,357 | ||||||||||||
| Depreciation | 741 | 5,978 | 1,795 | 12,775 | ||||||||||||
| Total operating expenses | 814,732 | 816,053 | 1,595,004 | 1,878,543 | ||||||||||||
| Operating income (loss) | 251,571 | (63,158 | ) | 442,554 | (536,492 | ) | ||||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 888 | 3,420 | 53,346 | 7,718 | ||||||||||||
| Interest expense | (2,217 | ) | (3,858 | ) | (4,679 | ) | (7,087 | ) | ||||||||
| Total other income (expense) | (1,329 | ) | (438 | ) | 48,667 | 631 | ||||||||||
| Net income (loss) | $ | 250,242 | $ | (63,596 | ) | $ | 491,221 | $ | (535,861 | ) | ||||||
| Weighted average common shares outstanding - basic | 13,175,433 | 11,939,169 | 12,560,716 | 11,764,086 | ||||||||||||
| Weighted average common shares outstanding - diluted | 13,551,931 | 11,939,169 | 12,937,216 | 11,764,086 | ||||||||||||
| Net income (loss) per common share - basic and diluted | $ | 0.02 | $ | (0.01 | ) | $ | 0.04 | $ | (0.05 | ) | ||||||
| -4- |
SYRA HEALTH CORP.
STATEMENTS OF CASH FLOWS
(Unaudited)
| For the Six Months Ended | ||||||||
| June 30, | ||||||||
| 2026 | 2025 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net income (loss) | $ | 491,221 | $ | (535,861 | ) | |||
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||||||||
| Depreciation | 1,795 | 12,775 | ||||||
| Common stock issued for services | - | 2,586 | ||||||
| Stock-based compensation | 44,439 | 54,067 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (551,649 | ) | (205,534 | ) | ||||
| Other current assets | 141,516 | 157,985 | ||||||
| Right-of-use asset | 29,877 | 277,029 | ||||||
| Accounts payable | (51,926 | ) | 455,366 | |||||
| Accounts payable, related party | 53,000 | - | ||||||
| Deferred revenue | 489,275 | 250,000 | ||||||
| Accrued expenses | 25,512 | (105,630 | ) | |||||
| Operating lease liability | (29,877 | ) | (277,029 | ) | ||||
| Net cash provided by operating activities | 643,183 | 85,754 | ||||||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Purchase of property and equipment | - | - | ||||||
| Net cash used in investing activities | - | - | ||||||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Proceeds from sale of common stock and exercise of warrants | - | 14,800 | ||||||
| Repayments on notes payable | (134,169 | ) | (190,035 | ) | ||||
| Net cash used in financing activities | (134,169 | ) | (175,235 | ) | ||||
| NET CHANGE IN CASH AND CASH EQUIVALENTS | 509,014 | (89,481 | ) | |||||
| CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | 1,614,733 | 2,395,405 | ||||||
| CASH AND CASH EQUIVALENTS AT END OF PERIOD | $ | 2,123,747 | $ | 2,305,924 | ||||
| SUPPLEMENTAL INFORMATION: | ||||||||
| Interest paid | $ | 4,679 | $ | 7,087 | ||||
| Income taxes paid | $ | - | $ | - | ||||
| NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||||||||
| Conversion of Class B common stock to Class A common stock | $ | 2,500 | $ | 2,333 | ||||
| Recognition of right-of-use asset and lease liability | $ | 80,120 | $ | - | ||||
| Prepaid asset financed with note payable | $ | 89,477 | $ | 123,866 | ||||
| -5- |
Non-GAAP Financial Measures
In addition to financial results reported in accordance with accounting principles generally accepted in the United States of America (“GAAP”), we have provided the following non-GAAP financial measure in this release and the accompanying tables: adjusted EBITDA. We use this non-GAAP financial measures internally to facilitate period-to-period comparisons and analysis of our operating performance and liquidity and believe it is useful to investors as a supplement to GAAP measures in analyzing, trending, and benchmarking the performance and value of our business. However, this measure is not intended to be a substitute for those reported in accordance with GAAP. These measures may be different from non-GAAP financial measures used by other companies, even when similar terms are used to identify such measures. For reconciliations of historical non-GAAP financial measures to the most comparable financial measures under GAAP, see the table below.
| Six Months Ended | ||||||||
| June 30, 2026 | June 30, 2025 | |||||||
| Net Income (Loss) | $ | 491,221 | $ | (535,861 | ) | |||
| Interest expense | 4,679 | 7,087 | ||||||
| Depreciation expense | 1,795 | 12,775 | ||||||
| Taxes | - | - | ||||||
| Earnings before Interest, Taxes Depreciation and Amortization | $ | 497,695 | $ | (515,999 | ) | |||
| Three Months Ended | ||||||||
| June 30, 2026 | June 30, 2025 | |||||||
| Net Income (Loss) | $ | 250,242 | $ | (63,596 | ) | |||
| Interest expense | 2,217 | 3,858 | ||||||
| Depreciation expense | 741 | 5,978 | ||||||
| Taxes | - | - | ||||||
| Earnings before Interest, Taxes Depreciation and Amortization | $ | 253,200 | $ | (53,760 | ) | |||
| -6- |
About Syra Health
Syra Health is an integrated healthcare solutions company serving government and commercial healthcare organizations with innovative solutions designed to improve health outcomes. We specialize in healthcare prevention, expanding access, and delivering affordable solutions. Our healthcare analytics capabilities provide proactive, actionable insights and data-driven intelligence, and our HIPAA-compliant and fully accessible digital health solutions enable measurable health outcomes in highly regulated healthcare environments. Through training and education, we help healthcare organizations reduce costs and deliver consistent, high-quality care.
Discover our healthcare solutions at www.syrahealth.com and follow the Company on LinkedIn.
Forward-Looking Statements
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include but are not limited to, statements relating to the expected use of proceeds, the Company’s operations and business strategy, and the Company’s expected financial results. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty, and changes in circumstances. Investors should read the risk factors set forth in our Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact
Christine Drury
IR/PR Director
Syra Health
christined@syrahealth.com
463-345-5180
| -7- |